Drug target for treating veterinary infections and methods of using same

Patent metadata

Field	Value
Publication number	US-10772900-B2
Application number	US-201716318769-A
Country	US
Kind code	B2
Filing date	Jul 21, 2017
Priority date	Jul 27, 2016
Publication date	Sep 15, 2020
Grant date	Sep 15, 2020

Abstract

The invention includes a method of treating or preventing a Staphylococcus infection in a mammal or avian species in need thereof. The methods comprise administering to the mammal or avian species a therapeutically effective amount of fosmidomycin. In certain embodiments, the methods treat or prevent a drug-resistant Staphylococccus infection.

First claim

What is claimed:

1. A method of treating a Staphylococcus infection in a mammal or avian species, wherein the Staphylococcus infection is caused by a species of Staphylococcus that utilizes the non-mevalonate pathway for isoprenoid biosynthesis, wherein the species of Staphylococcus that utilizes the non-mevalonate pathway for isoprenoid biosynthesis is not Staphylococcus hyicus ; the method comprising administering to the mammal or avian species in need thereof a therapeutically effective amount of fosmidomycin, or a salt, solvate, tautomer, enantiomer or diastereomer thereof, whereby the Staphylococcus infection is treated in the mammal or avian species.

2. The method of claim 1 , wherein the Staphylococcus infection is caused by at least one Staphylococcus species selected from the group consisting of S. schleiferi, S. pseudintermedius, S. sciuri, S. hyicus , and S. chromogenes.

3. The method of claim 1 , wherein the Staphylococcus infection is caused by an antibiotic resistant Staphylococcus.

4. The method of claim 1 , wherein the mammal or avian species is selected from the group consisting of a dog, pig, cow, horse, bird, and human.

5. The method of claim 1 , wherein the mammal comprises a dog.

6. The method of claim 1 , wherein fosmidomycin is administered to the mammal or avian species as a pharmaceutical composition further comprising at least one pharmaceutically acceptable carrier.

7. The method of claim 1 , wherein the mammal or avian species is further administered at least one antibacterial agent.

8. The method of claim 7 , wherein the fosmidomycin and the at least one antibacterial agent are co-administered to the mammal or avian species.

9. The method of claim 7 , wherein the fosmidomycin and the at least one antibacterial agent are co-formulated.

10. The method of claim 1 , wherein the fosmidomycin is administered to the animal by at least one administration route selected from the group consisting of otic, topical, inhalational, oral, rectal, vaginal, parenteral, intranasal, buccal, ophthalmic, intrathecal, intracranial, and intravenous.

11. The method of claim 1 , wherein the fosmidomycin is the only antibacterial agent administered to the mammal or avian species.

12. A method of treating a Staphylococcus schleiferi infection in a mammal or avian species, the method comprising administering to the mammal or avian species in need thereof a therapeutically effective amount of fosmidomycin, or a salt, solvate, tautomer, enantiomer or diastereomer thereof, whereby the Staphylococcus schleiferi infection is treated in the mammal or avian species.

13. The method of claim 12 , wherein the S. schleiferi infection is caused by an antibiotic resistant Staphylococcus.

14. The method of claim 12 , wherein the mammal or avian species is selected from the group consisting of a dog, pig, cow, horse, bird, and human.

15. The method of claim 12 , wherein the mammal comprises a dog.

16. The method of claim 12 , wherein fosmidomycin is administered to the mammal or avian species as a pharmaceutical composition further comprising at least one pharmaceutically acceptable carrier.

17. The method of claim 12 , wherein the mammal or avian species is further administered at least one antibacterial agent.

18. The method of claim 17 , wherein the fosmidomycin and the at least one antibacterial agent are co-administered to the mammal or avian species.

19. The method of claim 17 , wherein the fosmidomycin and the at least one antibacterial agent are co-formulated.

20. The method of claim 12 , wherein the fosmidomycin is administered to the animal by at least one administration route selected from the group consisting of otic, topical, inhalational, oral, rectal, vaginal, parenteral, intranasal, buccal, ophthalmic, intrathecal, intracranial, and intravenous.

21. The method of claim 12 , wherein the fosmidomycin is the only antibacterial agent administered to the mammal or avian species.

Assignees

• Univ Pennsylvania

Inventors

• Beiting Daniel P
• Misic Ana M
• Rankin Shelly C

Classifications

• C07F9/22

  Amides of acids of phosphorus · CPC title

• C07F9/46

  Phosphinous acids [R2POH], [R2P(= O)H]: Thiophosphinous acids {including[R2PSH]; [R2P(=S)H]; Aminophosphines [R2PNH2]; Derivatives thereof} · CPC title

• C07F9/38

  Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids {; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]} · CPC title

• C07F9/6587

  having two phosphorus atoms as ring hetero atoms in the same ring · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title